The study seeks to delve into the firsthand experiences of patients diagnosed with schizophrenia who partake in a separate clinical trial featuring a specific medical intervention. The primary emphasis will be on meticulously tracking the rates of trial completion and withdrawal among these individuals. The data collected from this study will help improve future outcomes for all schizophrenia patients as well as those in under-represented demographic groups.
Study Type
OBSERVATIONAL
Enrollment
500
Power Life Sciences
San Francisco, California, United States
Number of schizophrenia patients who decide to enroll in a clinical trial
Time frame: 3 months
Rate of schizophrenia patients who remain in clinical trial to trial completion
Time frame: 12 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.